Time is limited! Fill out the form on this page to see if you qualify.
An advocate or attorney will contact you within minutes for your free consultation.
No fees unless you are awarded compensation!
Actos, also known as Pioglitazone Hydrochloride, is an FDA approved drug used to treat Type 2 diabetes. Actos is manufactured by Takeda and Eli Lilly and is one of the most successful diabetes medications on the market. However, in recent years it was found that taking Actos for a prolonged period of time often lead to a 40% chance of bladder cancer.
In June 2011, the FDA warned the medical industry of the increased risk of Actos patients developing bladder cancer. The risk surfaced when an interim analysis was conducted on a ten-year epidemiological study. The results from the study revealed that patients who had the longest exposure and highest dosage of the Actos medication were at the greatest risk.
It's crucial that Actos patients who've been diagnosed with bladder cancer file a claim with a legal representative. An Actos attorney will help you fight for the financial compensation you're entitled to for damages, lost wages and excess medical expenses.
Actos lawsuits began to rise in August 2011 after the FDA discovered the link between prolonged Actos use and bladder cancer. Due to the negligence of the manufacturers Takeda and Eli Lilly, patients were not adequately warned of the adverse side effects. As a result many patients suffered physically, emotionally and financially.
In April 2014, the first Actos multidistrict litigation bellwether trial went to court. The plaintiff, Terrence Allen was diagnosed with bladder cancer in 2011 after taking Actos since 2006 to treat his Type 2 diabetes. A jury ultimately awarded Allen and his wife $1.5 million in damages. Since bellwether trials give a good indication of how future litigation will play out, Allen's settlement is a good sign for the thousands of Actos cases still awaiting trial.
Mounting evidence now exists between the use of the drug Actos and the development of bladder cancer, patients who have been impacted deserve compensation from the manufactures.
